Trial Profile
An Open-label, Multicenter, Phase 2 Trial Investigating the Efficacy and Safety of Daratumumab in Subjects With Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor and IMiD) or are Double Refractory to a Proteasome Inhibitor and an IMiD
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 26 Feb 2020
Price :
$35
*
At a glance
- Drugs Daratumumab (Primary)
- Indications Multiple myeloma
- Focus Registrational; Therapeutic Use
- Acronyms SIRIUS
- Sponsors Janssen Research & Development; Janssen-Cilag
- 20 Feb 2020 PK analysis results of splitting the first daratumumab IV dose into two separate infusions published in the Advances in Therapy
- 04 Dec 2018 Results of an indirect comparison of a Daratumumab Monotherapy Vs. EU Approved Comparator Therapies in Patients with Multiple Myeloma, presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
- 12 Dec 2017 Results from GEN501 and Sirius trials presented at the 59th Annual Meeting and Exposition of the American Society of Hematology